Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: A potential new risk factor for coronary artery disease

Atherosclerosis

Volumn 150, Issue 2, 2000, Pages 413-419

  Caslake, Muriel J ^a   Packard, Chris J ^a   Suckling, Keith E ^b   Holmes, Stephen D ^b   Chamberlain, Paul ^b   Macphee, Colin H ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Coronary artery disease; Lipoprotein associated phospholipase A2; Potential new risk factor

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; MONOCLONAL ANTIBODY; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID OXIDATION; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPIDS; MALE; MIDDLE AGED; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; PLATELET ACTIVATION; PROGNOSIS; RISK FACTORS;

EID: 0034035763     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00406-2     Document Type: Article

References (35)

1. Assmann G., Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease. Am. J. Cardiol. 70:1992;733-737.
2. Kwiterovich P.O. The antiatherogenic role of high density lipoprotein cholesterol. Am. J. Cardiol. 82:1998;13Q-21Q.
3. Witztum J.L., Steinberg D.J. Role of oxidised low density lipoprotein in atherogenesis. Clin. Invest. 88:1991;1785-1792.
4. Berliner J.A., Heinecke J.W. The role of oxidised lipoproteins in atherogenesis. Free Radic. Biol. Med. 20:1996;707-727.
5. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett. 286:1991;152-154.
6. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: biochemistry, genetics, and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7:1996;69-76.
7. Shih D.M., Gu L., Xia Y.R. et al. Nature. 394:1998;284-287.
8. Goyal J., Wang K., Liu M., Subbaiah P.V. Novel function of lecithin-cholesterol acyltransferase. J. Biol. Chem. 272:1997;16231-16239.
9. Berliner J., Leitinger N., Watson A., Huber J., Fogelman A., Navab M. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb. Haemost. 78:1997;195-199.
10. Stafforini D.M., McIntyre T.M., Carter M.E., Prescott S.M. Human plasma platelet-activating factor acetylhydrolase: association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem. 262:1987;4215-4222.
11. Steinbrecher U.P., Pritchard P.H. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet activating factor acetylhydrolase. J. Lipid Res. 30:1989;305-315.
12. Tew D.G., Southan C., Rice S.Q.J. et al. Purification, properties, sequencing and cloning of a lipoprotein associated, serine dependent phospholipase which is involved in the oxidative modification of low density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 16:1996;591-599.
13. 2 generates two bioactive products during the oxidation of low density lipoprotein: Studies using a novel inhibitor. Biochem. J. 338:1999;479-487.
14. 2 superfamily of signal transduction enzymes. TIBS. 22:1997;1-2.
15. Stremler K.E., Stafforini D.M., Prescott S.M., McIntyre T.M. Human platelet-activating factor acetylhydrolase: oxidatively fragmented phospholipids as substrates. J. Biol. Chem. 266:1991;11095-11103.
16. 2 in atherogenesis. Pharmacol. Rev. Commun. 8:1996;309-315.
17. Tjoelker L.W., Wilder C., Eberhardt C. et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 374:1995;549-553.
18. Ostermann G., Ruhling K., Zabel-Langhennig R., Winkler L., Schlag B., Till U. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. Thromb. Res. 47:1987;279-285.
19. Ostermann G., Lang A., Holtz H., Ruhling K., Winkler L., Till U. The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients. Thromb. Res. 52:1988;529-540.
20. Graham R.M., Stephens C.J., Sturm M.J., Taylor R.R. Plasma platelet-activating factor degradation in patients with severe coronary artery disease. Clin. Sci. 82:1992;535-541.
21. Satoh K., Yoshida H., Imaizumi T.A., Takamatsu S., Mizuno S. Platelet activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke. Stroke. 23:1992;1090-1092.
22. US Department Health, Education and Welfare. Lipid Research Clinics Program: Manual of Laboratory Operations Vol. 1: Lipid and Lipoprotein Analysis (publication no. (NIH) 75-628). Bethesda, MD: National Institutes of Health, 1975.
23. Zola H. Monoclonal Antibodies. A Manual of Techniques. 1987;1987 CRC Press, Boca Raton, FL.
24. Rice S., Southan C., Boyd H. et al. Expression, purification, and characterisation of a human serine dependent phospholipase with high specificity for oxidised phospholipids and platelet activating factor. Biochem. J. 330:1998;1309-1315.
25. Ostermann G., Kertscher H.P., Winkler L., Schlag B., Ruhling K., Till U. The role of lipoproteins in the degradation of platelet-activating factor. Thromb. Res. 44:1986;303-314.
26. Carter E., Wu L., Stafforini D.M. et al. Platelet-activating factor acetylhydrolase correlates with plasma lipoproteins. Arteriosclerosis. 8:1988;712a.
27. Guerra R., Zhao B., Mooser V., Stafforini D., Johnston J.M., Cohen J.C. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J. Lipid Res. 38:1997;2281-2288.
28. Mainard F., Ozanne P., Madec Y. Variations in lipoproteins, hormones and blood glucose during the early acute phase of myocardial infarction. Atherosclerosis. 69:1988;225-231.
29. Stephens C.J., Graham R.M., Sturm M.J., Richardson M., Taylor R.R. Variation in plasma platelet-activating factor degradation and serum lipids after acute myocardial infarction. Coron. Heart Dis. 4:1993;187-193.
30. Pritchard P.H., Chonn A., Yeung C.C.H. The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease). Blood. 66:1985;1476-1478.
31. Satoh K., Imaizumi T., Kawamura Y., Yoshida H., Takamatsu S., Takamatsu M. Increased activity of platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension. Prostaglandins. 37:1989;673-682.
32. Surya I.I., Mommersteeg M., Erkelens D.W., Akkerman J.-W.N. PAF-acetylhydrolase, predominantly present in LDL in healthy subjects, is associated with HDL in a patient with LDL deficiency. J. Lipid Med. 3:1991;27-38.
33. Karabina S.P., Liapikos T.A., Grekas G., Goudevenos J., Tselepis A.D. Distribution of PAF acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim. Biophys. Acta. 1213:1994;34-38.
34. Packard C.J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. 17:1997;3542-3556.
35. Chapman M.J., Guerin M., Bruckert E. Atherogenic, dense low density lipoproteins: pathophysiology and new therapeutic approaches. Eur. Heart J. 19((Suppl. A)):1998;A24-A30.